Session I – 202X Trends and Perspectives – Goals, Governance, Innovation, Immunization Strategy

Moderator: David Curry, CVEP
Panel:
Kim Mulholland, London School of Hygiene & Tropical Medicine
Future trends and perspectives in immunization
[slides: Global Vaccines 202X_Mulholland ]
[ video: Part I, Part II ]

Osagie Imasogie, UPenn Law, Phoenix IP Ventures
The Emergence  of Private, Mega Philanthropy Foundations and The Implications For Global Public Health
[slides: Global Vaccines 202X_Imasogie]
[ video: Part I, Part II ]

Tom Kosten, Baylor College of Medicine
Haptenated Vaccines: Addictions & Sustained Medications
[slides: Global Vaccines 202X_Kosten ]
[video: here ]

Sandy Wrobel, Applied Strategies
Vaccine Landscape: Implications for 202X
[slides: Global Vaccines 202X_Wrobel ]
[ video: here]

JM Okwo-Bele, WHO IVB
202X trends and perspectives – Immunization Strategy 
[slides: Global Vaccines 202X_Okwo ]
[video: here ]

[return to agenda]

Session Abstract
The Decade of Vaccines Collaboration has set the time window for its eventual Global Vaccine Action Plan (GVAP) beyond both the Global Immunization & Vaccine Strategy (GIVS: 2005-2015) and the MDGs (2015): The DoV Collaboration positions GIVS as a “springboard” for the eventual GVAP, although it is unclear how it will impact next GIVS planning cycle, or supporting and complementary planning such as the IVR Strategic Plan (2010-2020), which obviously already spans the decade:

Further, there seems to be no substantive engagement as yet in forging post-MDG goals and metrics overall or in global health: The Lancet and London International Development Centre Commission’s work (The Lancet, 13 Sep 2010) is a very interesting beginning, with workshops scheduled for February 2011 and thereafter:

Global health governance will also see evolution in the decade ahead, with the roles and TORs (terms of reference) of IGOs, NGOs, disease and vaccine-specific collaboratives, foundations, private donors, civil society organizations, and governments adapting to a fresh ecosystem of effort and responsibility:

This session will offer the Global Vaccines 202X symposium important opening perspectives on global immunization and vaccines in the decade-plus ahead, with a particular focus on access, equity and ethics.

Resources

Links:
London School of Hygiene & Tropical Medicine

Applied Strategies

WHO IVB

Serum Institute of India

.

The Lancet
Sep 18, 2010  Volume 376  Number 9745  Pages 929 – 1024
The Lancet Commissions
The Millennium Development Goals: a cross-sectoral analysis and principles for goal setting after 2015
Jeff Waage, Rukmini Banerji, Oona Campbell, Ephraim Chirwa, Guy Collender, Veerle Dieltiens, Andrew Dorward, Peter Godfrey-Faussett, Piya Hanvoravongchai, Geeta Kingdon, Angela Little, Anne Mills, Kim Mulholland, Alwyn Mwinga, Amy North, Walaiporn Patcharanarumol, Colin Poulton, Viroj Tangcharoensathien, Elaine Unterhalter
[Free pdf]
http://download.thelancet.com/flatcontentassets/pdfs/S0140673610611968.pdf

.
The Lancet
Sep 18, 2010  Volume 376  Number 9745  Pages 929 – 1024
Lancet Editorial: Equity as a shared vision for health and development (MDGs)

.
JAMA   
April 20, 2011, Vol 305, No. 15, pp 1511-1610
JAMA. 2011;305(15):1585-1586. Published online March 29, 2011. doi: 10.1001/jama.2011.418
Commentary: Medicine and Law
Reforming the World Health Organization
Devi Sridhar, DPhil; Lawrence O. Gostin, JD
[extract]
In December 2010, Jack Chow,1​ the former World Health Organization (WHO) assistant director-general, asked, “Is the WHO becoming irrelevant?” A month later, the WHO’s executive board considered the agency’s future within global health governance. After a year-long consultation with member states on its financing, Director-General Margaret Chan called the WHO overextended and unable to respond with speed and agility to today’s global health challenges.2

The crisis in leadership is not surprising to those familiar with the WHO. As its first specialized agency, the United Nations (UN) endowed the WHO with extensive normative powers to act as the directing and coordinating authority on international health. Yet modern global health initiatives (eg, the Global Fund to Fight AIDS, Tuberculosis and Malaria and the GAVI Alliance [formerly the Global Alliance for Vaccines and Immunisation]), bilateral programs (eg, US President’s Emergency Plan for AIDS Relief [PEPFAR]), and well-funded philanthropies (eg, the Bill & Melinda Gates Foundation) often overshadow the agency. The WHO can be subject to political pressure, and its relationship with industry and civil society is uncertain.3

Given the importance of global health cooperation, few would dispute that a stronger, more effective WHO would benefit all. The WHO’s internal reform agenda must be bold to ensure its future. In this Commentary, we offer 5 proposals for reestablishing the agency’s leadership….

Free full text: http://jama.ama-assn.org/content/305/15/1585.full

Nature  
Volume 472 Number 7341 pp5-130  7 April 2011
http://www.nature.com/nature/current_issue.html
Rare-disease project has global ambitions
Consortium aims for hundreds of new therapies by 2020.
Alison Abbott
Prader–Willi syndrome. Fabry renal disease. Spinocerebellar ataxia. Few people have heard of these and the other ‘rare diseases’, some of which affect only hundreds of patients worldwide. Drug companies searching for the next blockbuster pay them little attention. But the diseases are usually incurable — and there are thousands of them.
This week, the US National Institutes of Health (NIH) and the European Commission launch a joint assault on these conditions, whose small numbers of patients make it difficult to test new treatments and develop diagnostic methods. The International Rare Disease Research Consortium being formed under the auspices of the two bodies has the ambitious goal of developing a diagnostic tool for every known rare disease by 2020, along with new therapies to treat 200 of them. At the launch meeting in Bethesda, Maryland, on 6–8 April, prospective partners will map out research strategies to identify diagnostic biomarkers, design clinical trials and coordinate genome sequencing in these diseases. Nearly all the rare diseases, of which there are an estimated 6,000–8,000, are the result of small genetic changes.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: